| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:1583-1592.)
© 2005 American Heart Association, Inc.
Heart Failure |
From the Deutsches Herzzentrum and 1 Medizinische Klinik (S.M., C.M., B.J., M.V., R.W.); Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar (C.M.); and Institut für allgemeine Pathologie und pathologische Anatomie (S.S.), University of Technology (Technische Universität), Munich, Germany.
Correspondence to Dr Rainer Wessely, Deutsches Herzzentrum and 1 Medizinische Klinik, Technische Universität, Lazarettstrasse 36, 80636 München, Germany. E-mail rwessely{at}dhm.mhn.de
Received November 2, 2004; revision received November 19, 2004; accepted November 23, 2004.
Background Enteroviridae such as coxsackievirus B3 (CVB3) are important infectious agents involved in viral heart disease, hepatitis, and pancreatitis, but no specific antiviral therapy is available.
Methods and Results The aim of the present study was to evaluate the impact of RNA interference on viral replication, cytopathogenicity, and survival. Small interfering RNA (siRNA) molecules were designed against the viral 2A region (siRNA-2A), which is considered to be highly conserved and essential for both virus maturation and host cytopathogenicity. siRNA-2A exhibited a significant protective effect on cell viability mediated by marked inhibition of CVB3 gene expression and viral replication. In highly susceptible type I interferon receptorknockout mice, siRNA-2A led to significant reduction of viral tissue titers, attenuated tissue damage, and prolonged survival. Repeated siRNA-2A transfection was associated with a further improvement of survival. Various control siRNA molecules had no protective effect in vitro or in vivo.
Conclusions RNA interference directed against the 2A protease encoding genomic region effectively confers intracellular immunity toward CVB3-mediated cell injury and improves survival, suggesting a potential role for RNA interference for future treatment options targeting enteroviral diseases.
Key Words: coxsackievirus RNA enterovirus myocarditis protease
This article has been cited by other articles:
![]() |
H. S. Lee, J. Ahn, Y. Jee, I. S. Seo, E. J. Jeon, E.-S. Jeon, C. H. Joo, Y. K. Kim, and H. Lee Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region J. Gen. Virol., July 1, 2007; 88(7): 2003 - 2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yuan, D. A. Stein, T. Lim, D. Qiu, S. Coughlin, Z. Liu, Y. Wang, R. Blouch, H. M. Moulton, P. L. Iversen, et al. Inhibition of Coxsackievirus B3 in Cell Cultures and in Mice by Peptide-Conjugated Morpholino Oligomers Targeting the Internal Ribosome Entry Site J. Virol., December 1, 2006; 80(23): 11510 - 11519. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kusov, T. Kanda, A. Palmenberg, J.-Y. Sgro, and V. Gauss-Muller Silencing of Hepatitis A Virus Infection by Small Interfering RNAs. J. Virol., June 1, 2006; 80(11): 5599 - 5610. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |